Brooks Laboratories Limited
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and d… Read more
Brooks Laboratories Limited (BROOKS) - Net Assets
Latest net assets as of September 2025: ₹1.16 Billion INR
Based on the latest financial reports, Brooks Laboratories Limited (BROOKS) has net assets worth ₹1.16 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹1.40 Billion) and total liabilities (₹242.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹1.16 Billion |
| % of Total Assets | 82.65% |
| Annual Growth Rate | 25.03% |
| 5-Year Change | 23.95% |
| 10-Year Change | -19.62% |
| Growth Volatility | 93.21 |
Brooks Laboratories Limited - Net Assets Trend (2007–2025)
This chart illustrates how Brooks Laboratories Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Brooks Laboratories Limited (2007–2025)
The table below shows the annual net assets of Brooks Laboratories Limited from 2007 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹981.04 Million | +49.58% |
| 2024-03-31 | ₹655.85 Million | -11.32% |
| 2023-03-31 | ₹739.53 Million | -44.94% |
| 2022-03-31 | ₹1.34 Billion | +69.71% |
| 2021-03-31 | ₹791.48 Million | -19.58% |
| 2020-03-31 | ₹984.16 Million | -6.40% |
| 2019-03-31 | ₹1.05 Billion | -8.14% |
| 2018-03-31 | ₹1.14 Billion | -7.69% |
| 2017-03-31 | ₹1.24 Billion | +1.60% |
| 2016-03-31 | ₹1.22 Billion | +9.54% |
| 2015-03-31 | ₹1.11 Billion | -0.78% |
| 2014-03-31 | ₹1.12 Billion | +6.53% |
| 2013-03-31 | ₹1.05 Billion | +15.50% |
| 2012-03-31 | ₹912.63 Million | +369.77% |
| 2011-03-31 | ₹194.27 Million | +42.41% |
| 2010-03-31 | ₹136.42 Million | +59.80% |
| 2009-03-31 | ₹85.37 Million | +73.83% |
| 2008-03-31 | ₹49.11 Million | +179.29% |
| 2007-03-31 | ₹17.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Brooks Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48651700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹294.57 Million | 30.03% |
| Other Comprehensive Income | ₹2.81 Million | 0.29% |
| Other Components | ₹1.17 Billion | 119.28% |
| Total Equity | ₹981.04 Million | 100.00% |
Brooks Laboratories Limited Competitors by Market Cap
The table below lists competitors of Brooks Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MCKESSON
MU:MCK
|
$8.23 Million |
|
PESTECH International Bhd
KLSE:5219
|
$8.23 Million |
|
Ingram Micro Bilisim Sistemleri A.S.
IS:INGRM
|
$8.23 Million |
|
Magle Chemoswed Holding Ab
ST:MAGLE
|
$8.23 Million |
|
Mangal Credit and Fincorp Limited
NSE:MANCREDIT
|
$8.22 Million |
|
Bonk, Inc.
NASDAQ:BNKK
|
$8.22 Million |
|
DAP Corporation
KQ:066900
|
$8.22 Million |
|
SINTX Technologies Inc
NASDAQ:SINT
|
$8.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Brooks Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 655,853,000 to 981,043,000, a change of 325,190,000 (49.6%).
- Net loss of 99,670,000 reduced equity.
- Share repurchases of 425,043,000 reduced equity.
- New share issuances of 425,043,000 increased equity.
- Other comprehensive income decreased equity by 183,000.
- Other factors increased equity by 425,043,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹-99.67 Million | -10.16% |
| Share Repurchases | ₹425.04 Million | -43.33% |
| Share Issuances | ₹425.04 Million | +43.33% |
| Other Comprehensive Income | ₹-183.00K | -0.02% |
| Other Changes | ₹425.04 Million | +43.33% |
| Total Change | ₹- | 49.58% |
Book Value vs Market Value Analysis
This analysis compares Brooks Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.71x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 36.55x to 1.71x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-03-31 | ₹1.52 | ₹55.40 | x |
| 2008-03-31 | ₹4.17 | ₹55.40 | x |
| 2009-03-31 | ₹27.55 | ₹55.40 | x |
| 2010-03-31 | ₹11.61 | ₹55.40 | x |
| 2011-03-31 | ₹16.49 | ₹55.40 | x |
| 2012-03-31 | ₹47.01 | ₹55.40 | x |
| 2013-03-31 | ₹54.30 | ₹55.40 | x |
| 2014-03-31 | ₹57.85 | ₹55.40 | x |
| 2015-03-31 | ₹57.40 | ₹55.40 | x |
| 2016-03-31 | ₹62.87 | ₹55.40 | x |
| 2017-03-31 | ₹63.88 | ₹55.40 | x |
| 2018-03-31 | ₹58.97 | ₹55.40 | x |
| 2019-03-31 | ₹52.31 | ₹55.40 | x |
| 2020-03-31 | ₹55.34 | ₹55.40 | x |
| 2021-03-31 | ₹31.73 | ₹55.40 | x |
| 2022-03-31 | ₹35.07 | ₹55.40 | x |
| 2023-03-31 | ₹29.65 | ₹55.40 | x |
| 2024-03-31 | ₹25.60 | ₹55.40 | x |
| 2025-03-31 | ₹32.40 | ₹55.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Brooks Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.07%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.26x
- Recent ROE (-10.16%) is below the historical average (5.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 63.97% | 4.82% | 1.56x | 8.52x | ₹9.49 Million |
| 2008 | 65.71% | 11.46% | 1.11x | 5.17x | ₹27.36 Million |
| 2009 | 34.72% | 6.60% | 1.40x | 3.76x | ₹21.10 Million |
| 2010 | 37.91% | 11.48% | 1.21x | 2.73x | ₹38.08 Million |
| 2011 | 35.46% | 13.11% | 1.29x | 2.10x | ₹49.45 Million |
| 2012 | 9.68% | 15.76% | 0.53x | 1.16x | ₹-2.90 Million |
| 2013 | 6.78% | 8.92% | 0.61x | 1.25x | ₹-33.97 Million |
| 2014 | 6.45% | 8.49% | 0.61x | 1.25x | ₹-39.90 Million |
| 2015 | 8.50% | 11.11% | 0.63x | 1.21x | ₹-16.74 Million |
| 2016 | 8.71% | 13.29% | 0.52x | 1.25x | ₹-15.72 Million |
| 2017 | 1.58% | 3.40% | 0.35x | 1.32x | ₹-104.44 Million |
| 2018 | -12.07% | -24.79% | 0.32x | 1.51x | ₹-252.60 Million |
| 2019 | -14.08% | -26.90% | 0.33x | 1.60x | ₹-253.20 Million |
| 2020 | -24.77% | -35.26% | 0.44x | 1.60x | ₹-342.18 Million |
| 2021 | -24.48% | -25.14% | 0.48x | 2.05x | ₹-272.90 Million |
| 2022 | -22.07% | -21.18% | 0.47x | 2.24x | ₹-280.62 Million |
| 2023 | -28.26% | -33.45% | 0.57x | 1.48x | ₹-282.96 Million |
| 2024 | -29.87% | -24.65% | 0.88x | 1.38x | ₹-261.50 Million |
| 2025 | -10.16% | -12.07% | 0.67x | 1.26x | ₹-197.77 Million |
Industry Comparison
This section compares Brooks Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Brooks Laboratories Limited (BROOKS) | ₹1.16 Billion | 63.97% | 0.21x | $8.22 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |